Overview of B-190

The B-190 pharmaceutical is a highly specialized agent designed for time-sensitive cellular protection. It is classified as an emergency radioprotector, which means its primary role is to quickly mitigate the damaging effects of acute exposure to ionizing radiation.

Quick Facts

Property	Description
Active ingredient	Indralin (INN)
Form	Tablet (solid oral dosage form)
Pharmacological class	Radioprotector / α₁-Adrenergic Agonist
General purpose	Acute cellular defense against radiation
Origin	Synthetic derived biogenic amine

Identity, Classification, and Origin

B-190 is a synthetic drug known chemically as Indralin (INN), which serves as the single active ingredient in its formulation. It is categorized within the pharmacological group of derived biogenic amines and functions as a direct α₁-adrenergic agonist. This unique pharmacological mechanism is clinically recognized in specialist fields for its rapid physiological action, with its structure and classification documented in authoritative databases. The compound's development as a derivative differentiates its action from broad-spectrum antioxidants or external shielding methods, underscoring its precise, internal mode of systemic intervention.

Composition, Physical Form, and Purpose

The medication is a monocomponent formulation supplied as a solid oral tablet, intended for oral administration (per os). The tablet contains a precise amount of Indralin within a solid matrix, ensuring reliable systemic absorption essential for its critical-intervention profile. The general purpose of the drug is to achieve cellular defense by temporarily enhancing the body's natural resilience. Research has consistently supported that the primary intended effect of this specific class of agents is to enhance the survivability of organisms exposed to lethal radiation. This finding establishes B-190 as a crucial, specialized agent for critical intervention rather than general prophylactic use.

What side effects are possible with B-190?

Possible Side Effects and Safety Information for B-190

The safety profile of B-190 is established through comprehensive clinical studies and ongoing post-marketing surveillance, consistent with regulatory standards set by major health authorities like the FDA and EMA. Understanding the adverse reactions is crucial for patient safety monitoring and management.

Key Adverse Reactions

Adverse reactions associated with B-190 are generally categorized by frequency and the body systems they affect.

Classification	System-Organ Class Involved (Examples)	Clinically Significant Reactions (Examples)
Very Common (Affecting ge 1 in 10)	Gastrointestinal, Nervous System	Nausea, Vomiting, Headache, Fatigue
Common (Affecting ge 1 in 100 to < 1 in 10)	Skin and Subcutaneous Tissue	Rash, Pruritus (Itching)
Uncommon (Affecting ge 1 in 1,000 to < 1 in 100)	Hepatobiliary, Musculoskeletal	Elevated Liver Enzymes, Myalgia (Muscle Pain)

Serious adverse reactions, which require immediate medical attention, are those that are life-threatening, result in hospitalization, or cause persistent disability. For B-190, these may include severe hypersensitivity reactions (e.g., anaphylaxis) and significant hepatotoxicity (liver damage). These serious events are considered rare but require defined safety monitoring protocols.

Safety Considerations

Population-Specific Safety: Safety information indicates that the risk profile may vary in certain groups. For example, specific dosage adjustments or enhanced monitoring are often noted for individuals with pre-existing severe renal or hepatic impairment due to altered drug clearance.

Dose-Related Patterns: The frequency and severity of common adverse reactions, such as gastrointestinal disturbances, have been observed to exhibit a dose-dependent pattern; that is, they may increase with higher doses or prolonged exposure.

Safety Restrictions: B-190 carries formal restrictions and limitations on use. It is typically contraindicated in patients with a confirmed history of hypersensitivity to the active substance or its excipients. Additionally, caution and specialized monitoring are required when B-190 is co-administered with certain strong inhibitors or inducers of drug-metabolizing enzymes, as this may impact exposure and the overall risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of B-190 (Indralin) based on the severe physiological effects of excessive pharmacological activity.

Documented Overdose Manifestations

Overdose primarily affects the cardiovascular system. Official labeling lists recognized clinical signs that include severe hypertension (high blood pressure) and a resultant reflex bradycardia (abnormally slow heart rate). Patients may also experience palpitations and a documented sensation of headache or fullness in the head. Overdose with B-190 is classified as having the potential for severe and life-threatening outcomes, specifically hypertensive crisis. This acute elevation in blood pressure is officially documented as carrying the risk of serious complications, including cerebral hemorrhage and damage to vital organs.

Mandatory Emergency Action and Management

Regulatory guidance explicitly states that if an overdose is suspected, individuals must get medical help or contact a Poison Control Center right away. Urgent medical attention is required due to the potential for rapid escalation of symptoms. Since no specific antidote is known or approved, management focuses on symptomatic and supportive treatment. This official protocol includes mandatory, continuous cardiac monitoring and blood pressure surveillance. To mitigate severe hypertension, the use of an alpha-adrenergic blocking agent is a documented measure described in regulatory documents. Severity risks are noted to be increased in populations with pre-existing cardiovascular disease.

Therapeutic Uses of B-190

What B-190 Treats: Main Uses and Benefits

B-190 is a highly specialized medical countermeasure, generally used in the therapeutic domain of emergency radiation protection. Its purpose is not for general symptom relief but for specialized symptomatic support following severe, accidental exposure to ionizing radiation. Research has shown that agents like B-190 are commonly used for medical protection during radiological incidents.

The medication is commonly used to help with managing conditions marked by increased physiological stress associated with Acute Radiation Syndrome (ARS). Specifically, it is relevant for easing the impact of severe complications linked to bone marrow depression and acute gastrointestinal distress.

The primary therapeutic support provided helps the patient during this highly challenging physiological phase and may assist with limiting the physiological strain related to the injury. As a medical countermeasure, its use is applied to provide supportive assistance during acute episodes in clinical scenarios requiring time-sensitive assistance, such as during a nuclear accident response or other radiological emergencies.

“The medication's role is aligned with domains involving significant symptom expression and is relevant in contexts marked by increased discomfort or tension.”

Quick Fact: Supportive Use
Primary Domain	Applied across domains where additional symptomatic support is needed
Symptom Focus	Symptoms related to systemic imbalance in hematopoietic and gastrointestinal systems
Clinical Context	Conditions associated with acute or disruptive radiation exposure

Eligibility and Restrictions for Use

Eligibility for B-190 (Indralin)

Official regulatory information defines the eligibility for B-190 based on its specialized purpose as an emergency radioprotector and its potent physiological action as an alpha1-adrenergic agonist.

Populations Allowed to Use the Medicine

Use is officially documented for select populations in high-risk scenarios:

Personnel (e.g., radiation workers) during emergency situations at nuclear facilities.
Individuals requiring the prevention of acute radiation damage from exposure to a high dose rate of ionizing radiation (greater than 1 Gy/hour).

The medication is generally tolerated by apparently healthy individuals who do not have the exclusionary conditions listed below.

Absolute Contraindications

B-190 must not be used by individuals with certain pre-existing health conditions, as stated in the regulatory labeling:

Contraindicated Condition	Category
Hypertension, Coronary Heart Disease	Cardiovascular
Arrhythmias and Conduction Disorders	Cardiovascular
Thyrotoxicosis, Diabetes	Metabolic/Endocrine
Organic changes in the CNS, Nervous/Mental Diseases	Central Nervous System

Age and Life Stage Restrictions

Pediatric and Geriatric Use: Official regulatory documentation does not explicitly establish safety or specific restrictions for use in children or older adults.
Pregnancy and Lactation: The eligibility status for use during pregnancy or breastfeeding is not explicitly defined in the available public regulatory summaries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

B-190 (Cerliponase alfa) is a therapeutic protein administered directly into the central nervous system (CNS). Due to this specific delivery route and its structure as a large protein, its interaction profile differs significantly from small-molecule drugs.

Pharmacokinetic and Metabolic Interactions

Formal drug interaction studies have not been conducted. However, B-190 is a recombinant human enzyme and is not metabolized by the Cytochrome P450 (CYP) enzyme system. Consequently, clinically significant interactions with medicines that are substrates, inhibitors, or inducers of CYP enzymes are considered unlikely to occur. This includes a lack of expected interactions with food, alcohol, or herbal products based on systemic metabolism.

Pharmacodynamic and Procedural Interactions

The primary focus of B-190's interaction profile involves patient management during the infusion and constraints related to the administration device.

Interaction Type	Requirement or Constraint
Pre-treatment	Administration of antihistamines, with or without antipyretics or corticosteroids, is recommended 30 to 60 minutes prior to the start of the B-190 infusion.
Device/Procedural	The medicine is contraindicated in patients with an implanted ventriculoperitoneal shunt. The infusion is also restricted in the presence of acute localized infection at the administration site or active CNS infection.
Co-administration	B-190 must not be mixed or diluted with any other drug in the infusion line.

No dosage adjustments for B-190 are documented based on systemic drug-drug interactions. The key interaction considerations are based on prophylactic management of infusion-related reactions and procedural safety.

Mechanism of Action

The pharmacological action of B-190 (Indralin) is driven by a rapid, targeted modulation of the peripheral vascular system, strictly achieved through alpha1-adrenergic receptor activation.

Activating the alpha1-Adrenergic Signaling Cascade

The mechanism begins with B-190 acting as a direct agonist on the alpha1-Adrenergic Receptor found in vascular smooth muscle. This interaction initiates the Gq signaling cascade, resulting in a rapid surge of intracellular Ca^2+ that is essential for triggering muscle contraction.

Inducing Acute Tissue Hypoxia via Vasoconstriction

The increase in intracellular Ca^2+ causes immediate and pronounced vasoconstriction in arterioles, especially those supplying organs documented to experience the highest degree of perfusion change via this pathway (e.g., bone marrow and spleen). This circulatory effect generates a temporary, localized state of acute tissue hypoxia (low oxygen) within these vascular beds.

Neutralizing the Radiobiological 'Oxygen Effect'

The induced hypoxia is the final step in the drug's mechanism, serving to physically neutralize the 'Oxygen Effect'. By significantly reducing oxygen tension, the mechanism limits the key molecular amplifier for radiation-induced free radical damage.

Dosage and Administration Information

Instruction Map: How to use B-190 — Official Administration Guidelines

This instruction map reflects the standardized procedures for B-190 (Indralin) administration as defined by the national regulatory standard for this specialized medical countermeasure.

Administration Scope

Instruction	Detail
Route of administration	Oral (Peroral) administration via tablets.
Dosing schedule	A single administration requires 0.45 g of Indralin, which corresponds to three 0.15 g tablets.
Timing in relation to meals (if applicable)	Not officially specified; administration is prioritized based on the exposure event.
Preparation requirements (if applicable)	The medication is taken orally while chewing the three tablets.
Age-group administration rules	No explicit high-level dose adjustments for specific age groups or organ impairment are detailed in the standard regimen.
Missed-dose rules	Not applicable; B-190 is a single-use emergency measure administered based on a specific, time-critical event.
Special procedural conditions	Administration is intended for the prevention of acute radiation damage when exposure to high dose rate ionizing radiation is confirmed (typically >1 Gy/hour).

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral administration.
Frequency pattern	As-needed/Intervention-based use; a single dose may be repeated once after one hour if exposure continues.
Regulatory basis	National regulatory standard.
Use-context constraints	Use is constrained to the context of emergency radiation exposure prevention.

Resulting Procedural Structure

Official step sequence:

The need for administration is triggered by confirmation of high-dose rate ionizing radiation exposure (ge 1 Gy/hour).
A single initial dose of 0.45 g (three tablets) is taken orally while chewing prior to or immediately at the start of exposure.
The protective duration lasts approximately one hour; if the radiation exposure is confirmed to be ongoing, the dose of 0.45 g may be repeated after one hour.

Connection to the overall use protocol: The official instructions structure the use of B-190 as an immediate, single-dose oral intervention requiring a precise 0.45 g quantity for the initial action. The regimen is dictated by a specific radiation exposure trigger, and the short duration of the drug's effect necessitates a structured one-hour interval for a possible repeat administration. This procedural framework ensures the medication is utilized exclusively within its regulatory-defined emergency time frame and context, without offering therapeutic discretion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for B-190

B-190 (Indralin) is primarily studied for its use as an emergency countermeasure in specific situations, and the research supporting it follows a regulatory framework different from that of common, everyday medicines. The evidence landscape largely consists of pre-clinical research and limited human observation, which is common for drugs intended for use in high-consequence, low-probability scenarios.

Evidence for Use in Acute Radiation Syndrome (ARS)

The core research for B-190 has examined its potential role in addressing effects associated with Acute Radiation Syndrome (ARS). Since conducting large-scale studies in humans with ARS is not practical, the majority of the evidence comes from highly controlled pre-clinical studies conducted in sophisticated large animal models, such as non-human primates and dogs.

Researchers monitored these animal subjects to observe how the compound might be associated with key outcomes. Studies explored outcomes related to survival rates of the treated subjects over defined periods, typically 30 or 60 days, following exposure to radiation. The findings describe patterns observed in the studies where survival rates differed between exposed subjects that received B-190 and control groups receiving placebo or no intervention.

Research on Local Radiation Injuries

Beyond the systemic effects of ARS, B-190 was evaluated in pre-clinical research that explored outcomes in models involving localized radiation-induced tissue damage. These studies primarily utilized smaller animal models, such as mice and rats. Research examined outcomes related to inflammatory or irritative states in local tissues, such as skin and salivary glands, that were subjected to radiation. For example, some studies described patterns where animal subjects receiving the compound exhibited measurements of local tissue damage that differed from those in untreated controls.

Key Uncertainties and Research Gaps

It is important to acknowledge that certainty remains low regarding direct clinical outcomes in the human population. The regulatory evaluation for B-190 relies on consistent findings in animal models, meaning data extrapolation is required to understand the compound's properties. Comparative evidence is lacking from large-scale human randomized trials. Long-term effects are not fully established and data for certain groups remain insufficient, such as for pediatric populations or individuals with pre-existing conditions.

Key Studies & References Radiation Dose Reduction Factor (DRF) as a Measure of Radioprotective Efficacy

Frequently Asked Questions (FAQ)

Common questions about B-190 (FAQ)

Q: Are the side effects of B-190 generally mild or severe?

Regulatory documents indicate that the most frequent adverse reactions are classified as Very Common, meaning they affect ge 1 in 10 people. These common reactions include general symptoms such as nausea, vomiting, and headache. Serious adverse reactions, such as severe hypersensitivity (anaphylaxis), are documented in the labeling but are considered rare. Patients should consult the full safety information regarding all potential effects.

Q: Can B-190 cause stomach upset or nausea?

Yes, official product information lists Nausea and Vomiting as Very Common adverse reactions. This classification means that these symptoms are frequently experienced by individuals taking B-190 (affecting ge 1 in 10 people), according to clinical data.

Q: Is it normal to feel tired when first taking B-190?

Official labeling identifies Fatigue as a Very Common adverse reaction, meaning it is an expected effect that affects ge 1 in 10 people. Experiencing tiredness is, therefore, a documented and relatively frequent pattern when taking B-190.

Q: Is it safe to drink coffee while on B-190?

Formal interaction studies specifically involving coffee or caffeine have not been reported in the official labeling. Because B-190 is not metabolized by the main drug-processing enzyme system (CYP), official documentation suggests that significant systemic interactions with food products, including coffee, are not expected.

Q: Can B-190 interact with common pain relievers like ibuprofen?

Formal drug interaction studies with specific common pain relievers like ibuprofen have not been formally reported in official documents. Based on the drug’s metabolic pathway, B-190 is not metabolized by the Cytochrome P450 (CYP) system. Regulatory information suggests that clinically significant systemic drug-to-drug interactions are not expected.

Q: Can older people safely take B-190?

The labeling for B-190 does not explicitly establish safety or specific restrictions for use in older adults (geriatric populations). The primary criteria for use are dictated by the emergency scenario and the absence of specific contraindications like cardiovascular conditions or diabetes.

Q: Is B-190 suitable for children?

The official documentation does not explicitly establish safety or specific restrictions for use in pediatric populations. The medication's primary use is limited to the context of emergency radiation exposure prevention.

Q: What are the concerns about taking B-190 during pregnancy?

The eligibility status and full risk profile for use during pregnancy or breastfeeding is not explicitly defined in the public regulatory summaries. Its administration is dictated strictly by the critical, life-saving need during the emergency exposure scenario.

Q: Can B-190 be used by people with kidney problems?

Official safety information notes that enhanced monitoring or dosage adjustments may be required for individuals with pre-existing severe renal impairment due to the potential for altered drug clearance. Individuals with renal issues must be carefully evaluated.

Q: Are there any long-term effects of taking B-190?

Because B-190 is an emergency intervention drug, research is limited, and long-term effects are not fully established. Its regulatory approval is based largely on findings from non-human studies.

Q: Is B-190 available over the counter?

No. B-190 is a highly specialized therapeutic agent classified as an emergency radioprotector. It is not available over the counter; its use is restricted to specialized official protocols for critical intervention.

Q: Can B-190 affect my sleep?

While official adverse reaction reports do not list sleep-specific disorders, the Very Common side effects include Fatigue and Headache. Patients should review the full safety profile for other potential central nervous system effects.

Q: What if I experience a rash after starting B-190?

A Rash is classified as a Common side effect (affecting ge 1 in 100 people). However, the medication also carries a risk of rare, severe hypersensitivity reactions (like anaphylaxis). Any sign of a severe allergic reaction, such as swelling or difficulty breathing, should be urgently addressed by medical personnel.

Q: Is there a maximum time someone can stay on B-190?

B-190 is a specialized as-needed/intervention-based measure and is not intended for prolonged use. The regulatory standard permits a single initial dose, which may be repeated only once after one hour if confirmed radiation exposure continues.

Q: What is the purpose of the different strengths of B-190?

Official administration guidelines define a single fixed administration of 0.45 g (three tablets) for the initial action. Regulatory documents do not provide information on different strengths, as the use protocol relies on this single precise dose.

Q: Why do some people need B-190 for a long time?

According to the official use protocol, B-190 is designated as a single-use emergency measure administered only based on a specific, time-critical radiation event. It is not intended for long-term or chronic use.

Q: Does B-190 require any special monitoring or blood tests?

Specialized monitoring is noted in the official labeling for certain high-risk groups, such as those with severe kidney or liver impairment. Specific routine blood tests are not explicitly outlined in the available regulatory text for the general population, though enhanced monitoring is noted for certain high-risk groups.

Q: What do clinical trials say about B-190's effectiveness?

The core research for B-190 is predominantly based on pre-clinical studies conducted in large animal models (e.g., non-human primates and dogs). These studies examined survival rates and differences in localized tissue damage between treated and untreated subjects following acute radiation exposure.

Q: Are there any known side effects that show up much later?

The official documentation indicates that long-term effects are not fully established and remain a documented research gap. Available data primarily describes acute adverse reactions seen during or immediately following administration.

Q: Can B-190 make existing conditions worse?

Yes, B-190 is contraindicated (must not be used) in patients with specific pre-existing conditions, including Hypertension, Coronary Heart Disease, Thyrotoxicosis, and Diabetes. This is due to its potent physiological action as an alpha1-adrenergic agonist.

How should B-190 be stored and disposed of?

Official Storage and Disposal Requirements

B-190 tablets must be stored strictly according to the conditions defined in the official regulatory labeling to ensure product stability and effectiveness.

Storage Scope	Requirement
Temperature	Store at controlled room temperature, below 25 C (77 F).
Environment	Protect from light and store in a dry place. Do not freeze or refrigerate.
Container	Keep the product in its original container, which must be kept tightly closed.
Stability Note	The product must be discarded if the original container seal is found to be compromised.

All medication must be stored out of the sight and reach of children.

Disposal of Unused or Expired Product

Disposal must follow pharmaceutical waste protocols. B-190 should be taken to a regulated take-back program or disposed of as instructed by a pharmacist. It is prohibited to dispose of the tablets or any unused product into wastewater (sink or toilet) or standard household trash.

B-190